Motilal Oswal: Piramal Enterprises’ Lending Business Stable In Q2, Pharma Showing Healthy Traction
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Piramal Enterprises Ltd. reported 3% YoY growth in profit after tax to Rs 6.3 billion.
The lending book was stable QoQ at Rs 515 billion; however, decline in yield by 40 basis point QoQ led to 20 basis point margin contraction to 6.3%.
Asset quality was stable, with gross non-performing asset at 2.5% and emerging corporate lending provisions remaining high at 5.9% of loans.
Pharma business sales grew 10% YoY and Ebitda margins were stable at 23% YoY. Net debt in this business post the stake sale stands at Rs 22–25 billion.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.